Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) have been given a consensus rating of “Moderate Buy” by the five ratings firms that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $9.40.

A number of research analysts have commented on AMRX shares. JPMorgan Chase & Co. upgraded Amneal Pharmaceuticals from an “underweight” rating to a “neutral” rating and set a $9.00 price objective on the stock in a research report on Friday, September 6th. Barclays increased their price objective on Amneal Pharmaceuticals from $8.00 to $10.00 and gave the company an “overweight” rating in a research report on Tuesday, August 13th. Finally, Truist Financial increased their price target on Amneal Pharmaceuticals from $10.00 to $12.00 and gave the company a “buy” rating in a research note on Wednesday.

Amneal Pharmaceuticals Stock Up 1.2 %

NASDAQ AMRX opened at $8.65 on Tuesday. The firm has a market cap of $2.67 billion, a PE ratio of -15.45 and a beta of 1.18. Amneal Pharmaceuticals has a one year low of $3.36 and a one year high of $8.94. The stock’s 50 day simple moving average is $8.16 and its 200 day simple moving average is $7.08. The company has a debt-to-equity ratio of 121.31, a current ratio of 1.33 and a quick ratio of 0.82.

Amneal Pharmaceuticals (NASDAQ:AMRX) last announced its quarterly earnings data on Friday, August 9th. The company reported $0.15 EPS for the quarter, beating analysts’ consensus estimates of $0.11 by $0.04. The firm had revenue of $701.78 million for the quarter, compared to analyst estimates of $657.43 million. Amneal Pharmaceuticals had a positive return on equity of 1,235.03% and a negative net margin of 6.72%. As a group, sell-side analysts forecast that Amneal Pharmaceuticals will post 0.52 earnings per share for the current fiscal year.

Institutional Trading of Amneal Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in AMRX. Vanguard Group Inc. raised its stake in shares of Amneal Pharmaceuticals by 0.6% in the 1st quarter. Vanguard Group Inc. now owns 13,728,233 shares of the company’s stock valued at $83,193,000 after purchasing an additional 85,846 shares during the period. Rubric Capital Management LP grew its holdings in shares of Amneal Pharmaceuticals by 12.4% in the 2nd quarter. Rubric Capital Management LP now owns 10,721,778 shares of the company’s stock valued at $68,083,000 after acquiring an additional 1,179,830 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in shares of Amneal Pharmaceuticals by 17.6% in the 2nd quarter. Dimensional Fund Advisors LP now owns 4,283,928 shares of the company’s stock valued at $27,205,000 after acquiring an additional 641,405 shares in the last quarter. Nantahala Capital Management LLC grew its holdings in shares of Amneal Pharmaceuticals by 1.9% in the 2nd quarter. Nantahala Capital Management LLC now owns 2,669,943 shares of the company’s stock valued at $16,954,000 after acquiring an additional 50,000 shares in the last quarter. Finally, BlackBarn Capital Partners LP grew its holdings in shares of Amneal Pharmaceuticals by 41.5% in the 2nd quarter. BlackBarn Capital Partners LP now owns 2,000,000 shares of the company’s stock valued at $12,700,000 after acquiring an additional 586,703 shares in the last quarter. Institutional investors and hedge funds own 31.82% of the company’s stock.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.